At least one published report of an Advisory Committee meeting to, among other matters, discuss Schering-Plough's Pegintron, for [additional] melanoma indications (and some earlier Schering-Plough hedging on that score), is out tonight:
. . . .Meeting on Glaxo Smith Kline PLC's proposed candidate Votrient, for kidney cancer. . . . and Pegintron for use in addition to surgery for melanoma at an October 5, 2009 Advisory Committee meeting. . . .
No web-agenda, or meeting materials are up, yet though. I will keep readers posted.
Interesting how this information got in the British press on Monday the 24th. I just checked and it is definitely in today's Federal Register Friday Aug 25th.
ReplyDeleteI would think that discussions between the FDA and the regulated industry might very well occur prior to a public announcement however, somebody seems to have spoken with the press (or they ran it) prematurely.
The lesson I take away from this is how much easier it is for corporations to get things into the media whereas important stories go wanting.
Thank god for bloggers.
Salmon
P.S. I have on occasion thought of having a blog myself but you need a regular source of information to gain and hold regular readers. For me, I find things when I find them, so I have not felt that I have the timely material to keep a regular readership. Consequently I find it easier to comment on things as they appear and hopefully I can add perspectives from what I've gained from elsewhere on the web at various times.
I think the reason you gained my interest is because you have a specific subject matter with regular and otherwise not readily accessible material. It's related to my own interests (psychiatric drugs) and you provide perspective that I do not have the expertise to entertain.
Thank you.